Radiotherapy followed by high dose busulfan and thiotepa: A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas

Cancer

Volumn 88, Issue 3, 2000, Pages 685-692

  Bouffet, Eric ^a,h   Raquin, Marianne ^b   Doz, Francois ^c   Gentet, Jean Claude ^d   Rodary, Chantal ^b   Demeocq, Francois ^e   Chastagner, Pascal ^f   Lutz, Patrick ^g   Hartmann, Olivier ^b   Kalifa, Chantal ^b  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT CURIE   (France)

^d TIMONE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

^f HÔPITAL D ENFANTS   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Brainstem; Busulfan; Child; High dose chemotherapy; Radiotherapy; Thiotepa

Indexed keywords

BUSULFAN; THIOTEPA;

ADOLESCENT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; GLIOMA; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW TRANSPLANTATION; BRAIN STEM NEOPLASMS; BUSULFAN; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; GLIOMA; HUMANS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; STEREOTAXIC TECHNIQUES; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0034142195     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000201)88:3<685::AID-CNCR27>3.0.CO;2-K     Document Type: Article

References (46)

1. Robertson PL, Allen JC, Abbott IR, Miller DC, Fidel J, Epstein FJ. Cervicomedullary tumors in children - a distinct subset of brain-stem gliomas. Neurology 1994;44:1798-803.
2. Pierre-Kahn A, Hirsch JF, Vinchon M, Payan C, Sainte-Rose C, Renier D, et al. Surgical management of brain-stem tumors in children: results and statistical analysis of 75 cases. J Neurosurg 1993;79:845-52.
3. Robertson PL, Muraszko KM, Brunberg JA, Axtell RA, Dauser RC, Turrisi AT. Pediatric midbrain tumors: a benign subgroup of brainstem gliomas. Pediatr Neurosurg 1995;22(2): 65-73.
4. Constantini S, Epstein F. Surgical indication and technical considerations in the management of benign brain stem gliomas. J Neuro-Oncol 1996;28:193-205.
5. Zimmerman RA. Neuroimaging of primary brainstem gliomas: diagnosis and course. Pediatr Neurosurg 1996;25:45-53.
6. Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 1993;33:1026-9.
7. Kaplan AM, Albright AL, Zimmerman RA, Rorke LB, Li H, Boyett JM, et al. Brain-stem gliomas in children - a Children's Cancer Group review of 119 cases. Pediatr Neurosurg 1996;24:185-92.
8. Edwards MSB, Wara WM, Urtasun RC, Prados M, Levin VA, Fulton D. et al. Hyperfractionated radiation therapy for brain-stem glioma: a Phase I-II trial. J Neurosurg 1989;70: 691-700.
9. Freeman CR, Krischer J, Sanford RA, Cohen ME, Burger PC, Kun L, et al. Hyperfractionated radiation therapy in brainstem tumors. Cancer 1991;68:474-81.
10. Kretschmar CS, Tarbell NJ, Barnes PD, Krischer JP, Burger PC, Kun L. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors: a Phase II study of the Pediatric Oncology Group, protocol 8833. Cancer 1993;72:1404-13.
11. Packer RJ, Boyett JM, Zimmerman RA, Rorke LB, Kaplan AM, Albright AL, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas: a Children's Cancer Group Phase I/II trial. Cancer 1993;72:1414-21.
12. Packer RJ, Boyett JM, Zimmerman RA, Albright AL, Kaplan AM, Rorke LB et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Children's Cancer Group Phase I/II trial. Cancer 1994;74:1827-34.
13. Prados MD, Wara WM, Edwards MSB, Larson DA, Lamborn K, Levin VA. The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 1995;32:85-91.
14. Lewis J, Lucraft H, Gholkar A. UKCCSG study of accelerated radiotherapy for pediatric brain stem gliomas. United Kingdom Childhood Cancer Study Group. Int J Radiat Oncol Biol Phys 1997;38:925-9.
15. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 1998;40:265-71.
16. Allen JC, Siffert J. Contemporary chemotherapy issues for children with brainstem gliomas. Pediatr Neurosurg 1996; 24:98-102.
17. Kalifa C, Hartmann O, Demeocq F, Vassal G, Couanet D, Terrier Lacombe MJ, et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a Phase II study. Bone Marrow Transplant 1992;9:227-33.
18. Kedar A, Maria BL, Graham Pole J, Ringdahl DM, Quisling RG, Mickle JP, et al. High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors. Med Pediatr Oncol 1994;23: 428-36.
19. Mahoney DH Jr., Strother D, Camitta B, Bowen T, Ghim T, Pick T, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot Pediatric Oncology Group study. J Clin Oncol 1996;14:382-8.
20. Finlay JL, Goldman S, Wong MC, Cairo M, Garvin J, August C, et al. Pilot-study of high-dose thiotepa and etoposide with autologous bone-marrow rescue in children and young-adults with recurrent CNS tumors. J Clin Oncol 1996; 14:2495-503.
21. Graham ML, Herndon JE II, Casey JR, Chaffee S, Ciocci GH, Krischer JP, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997;15:1814-23.
22. Bouffet E, Mottolese C, Jouvet A, Philip I, Frappaz D, Carrie C, et al. Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 1997;33:91-5.
23. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7.
24. Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM, et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989;7:1288-94.
25. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
26. Bellissant E, Benichou J, Chastang C. Application of the triangular test to Phase II cancer clinical trials. Stat Med 1990;9:907-17.
27. Friedman HS, Krischer JP, Burger P, Oakes WJ, Hockenberger B, Weiner MD, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized Phase II study. J Clin Oncol 1992;10:249-56.
28. Heideman RL, Packer RJ, Reaman GH, Allen JC, Lange B, Horowitz ME, et al. A Phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 1993; 72:271-5.
29. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996;78: 527-31.
30. Lashford LS, Pearson ADJ, Thiesse P, Jasparn T, Vassal G, Dugan M, et al. Efficacy of Temodal in diffuse intrinsic brain stem gliomas (BSG) [abstract]. Proc ASCO 1998;17:544a.
31. Allen JC, Hancock C, Walker R, Tan C. PCNU and recurrent childhood brain tumors. J Neuro-Oncol 1987;5:241-4.
32. Allen JC, Bloom J, Ertel I, Evans A, Hammond D, Jones H, et al. Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. Semin Oncol 1986;13:110-22.
33. Chamberlain MC. Recurrent brainstem gliomas treated with oral VP-16. J Neuro-Oncol 1993;15:133-9.
34. Jenkin RDT, Boesel C, Ertel I, Evans A, Hittle R, Ortega J, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Children's Cancer Study Group. J Neurosurg 1987;66:227-33.
35. Fulton DS, Levin VA, Wara WM, Edwards MS, Wilson CB. Chemotherapy of pediatric brain-stem tumors. J Neurosurg 1981;54:721-5.
36. Wolff JE, Boos J, Kuhl J. HIT-GBM: Multizentrische Studie zur Behandlung von Kindern mit malignen Gliomen. Klin Padiatr 1996;208:193-6.
37. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989;24:386-90.
38. Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989;49:736-41.
39. Aaron RH, Elion GB, Colvin OM, Graham M, Keir S, Bigner DD, et al. Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 1994; 35:127-31.
40. Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr., et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48:4189-95.
41. Vassal G, Hartmann O, Habrand JL, Pico JL, Lemerle J. Enhanced cutaneous radiation effects following high-dose busulfan therapy. Cancer Chemother Pharmacol 1989;23: 117-8.
42. Dunkel IJ, Garvin JH Jr., Goldman S, Ettinger LJ, Kaplan AM, Cairo M, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group. J Neuro-Oncol 1998; 37:67-73.
43. Smith RR, Zimmerman RA, Packer RJ, Hackney DB, Bilaniuk LT, Sutton LN, et al. Pediatric brainstem glioma. Post-radiation clinical and MR follow-up. Neuroradiology 1990;32: 265-71.
44. Kramer ED, Packer RJ, Ginsberg J, Goldman S, Thompson S, Bayer LA, et al. Acute neurologic dysfunction associated with high-dose chemotherapy and autologous bone marrow rescue for primary malignant brain tumors. Pediatr Neurosurg 1997;27:230-7.
45. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei Lahr D, et al. High-dose N,N′,N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies. Semin Oncol 1990;17(Suppl 3):2-6.
46. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992;10: 135-41.